London-based Clarivate (NYSE:CLVT), a global provider of transformative intelligence solutions for scientific research, intellectual property, and life sciences, reported fourth-quarter and full-year 2025 results on February 24, 2026, highlighting enhanced cash generation, progress in subscription-based revenue mix, and strategic actions to streamline the portfolio and strengthen the balance sheet.
For the full year 2025, total revenue reached $2,455.2 million.
Organic Annual Contract Value (ACV), a key metric reflecting subscription momentum, increased 1.8% year-over-year, driven by solid retention and new sales in core segments including Intellectual Property, Science & Academia, and select Life Sciences offerings.
Free cash flow for 2025 improved significantly to $365.3 million, reflecting disciplined cost management, working capital efficiencies, and reduced capital intensity following prior divestitures and operational streamlining.
Clarivate also announced it is pursuing a strategic sale process for its Life Sciences & Healthcare business, aiming to unlock value and focus resources on higher-growth, higher-margin core operations in intellectual property management, scientific research, and academic solutions.
The potential transaction is expected to further simplify the portfolio and support deleveraging.
During 2025, the company returned approximately $225 million to shareholders through share repurchases and accelerated debt repayments to reduce leverage and interest expense.
For 2026, Clarivate provided guidance projecting organic ACV growth of 2% to 3%, adjusted EBITDA in the range of $980 million to $1.04 billion, and approximately 10% growth in free cash flow.